Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pseudomonas exotoxin--immunotoxins.

D J FitzGerald, M C Willingham, I Pastan

    Cancer Treatment and Research
    |January 1, 1988
    PubMed
    Summary
    This summary is machine-generated.

    Monoclonal antibodies conjugated with Pseudomonas exotoxin (PE) create potent immunotoxins (ITs) for cancer therapy. These PE-based ITs demonstrate significant antitumor activity in ovarian cancer models, outperforming other toxin conjugates.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Essential role for Bim in mediating the apoptotic and antitumor activities of immunotoxins.

    Oncogene·2017
    Same author

    Proteomic signatures of antiplatelet drugs: new approaches to exploring drug effects.

    Journal of thrombosis and haemostasis : JTH·2015
    Same author

    Blood volumes in cardiac surgery with cardiopulmonary bypass.

    Perfusion·2014
    Same author

    Blood volume measurement by hemodilution: association with valve disease and re-evaluation of the Allen Formula.

    Perfusion·2014
    Same author

    Commentary on: case report: The use of zero-balance ultrafiltration to correct acute metabolic acidosis after prolonged hypothermic circulatory arrest.

    Perfusion·2012
    Same author

    Antiplatelet and anticoagulant therapy during coronary thrombolysis.

    Trends in cardiovascular medicine·2011
    Same journal

    Clinical Trials and Translational Advances in Metabolic Targeting.

    Cancer treatment and research·2026
    Same journal

    Tools and Technologies for Studying Cancer Metabolism.

    Cancer treatment and research·2026
    Same journal

    Cancer and Immune Cells: A Metabolic Battle in the Tumor Microenvironment.

    Cancer treatment and research·2026
    Same journal

    Biomarkers of Cancer Metabolism and Therapeutic Response.

    Cancer treatment and research·2026
    Same journal

    Targeting Metabolism in Cancer Therapy: Inhibitors and Approaches.

    Cancer treatment and research·2026
    Same journal

    Metabolic Reprogramming in Cancer Stem Cells.

    Cancer treatment and research·2026
    See all related articles

    Area of Science:

    • Biochemistry
    • Immunology
    • Oncology

    Background:

    • Monoclonal antibodies (mAbs) are crucial for targeted therapies.
    • Pseudomonas exotoxin (PE) is a potent toxin for developing immunotoxins (ITs).
    • Developing effective cancer therapeutics remains a significant challenge.

    Purpose of the Study:

    • To evaluate the efficacy of PE-conjugated immunotoxins (PE-ITs) against ovarian cancer.
    • To compare the potency of PE-ITs with other toxin conjugates.
    • To understand the structure-function relationship of PE for improved IT design.

    Main Methods:

    • Coupling of monoclonal antibodies with PE to create ITs.
    • In vivo testing of PE-ITs (PE-HB21 and OVB-3-PE) in a nude mouse model of ovarian cancer.

    Related Experiment Videos

  • Deletion analysis of the PE structural gene.

    • Main Results:

    • Two PE-ITs, PE-HB21 and OVB-3-PE, exhibited significant antitumor activity in ovarian cancer models.
    • PE-ITs were at least 10-fold more potent than Ricin Toxin A (RTA)-based ITs.
    • Functional domains of PE were identified through deletion analysis.

    Conclusions:

    • PE-conjugated immunotoxins represent a potent therapeutic strategy for ovarian cancer.
    • Further development of ITs using recombinant PE is a promising avenue for cancer treatment.
    • Understanding PE's structure-function relationship aids in designing more effective targeted therapies.